Adult Male Hypogonadism: A Review

JAMA review puts obesity-driven low T (2–8% prevalence) well ahead of true gonadal failure (<1%), with weight loss as first-line.

Journal: JAMA | Published: 2026-06-23 | Type: Narrative Review | PMID: 42207626 Authors: Bradley D. Anawalt, Kim M. O'Connor (University of Washington), Mathis Grossmann (University of Melbourne) Funding/COI: Not disclosed

Summary

Most men diagnosed with hypogonadism have obesity to blame, not broken testes or a failed pituitary. True organic hypogonadism — from pathology of the hypothalamus, pituitary, or testes — affects fewer than 1% of men; obesity-related secondary hypogonadism hits 2–8%. The review argues that testosterone therapy is appropriate only for permanent hypogonadism or cases where the causative medication cannot be stopped, and that weight loss is the correct first move for everyone else.

Claims

• Prevalence of organic hypogonadism (hypothalamic, pituitary, or testicular pathology): <1% of men
• Prevalence of obesity-induced hypogonadism (BMI ≥30): 2–8%
• Klinefelter syndrome (≥2 X chromosomes, 1 Y) affects 2 in 1000 men and is frequently undiagnosed; it is the most common cause of primary hypogonadism
• Most common permanent causes of secondary hypogonadism: head/neck radiation and severe head trauma
• Most common reversible causes: obesity, severe illness, opioids, corticosteroids, checkpoint inhibitors, and medications causing hyperprolactinemia
• Diagnostic threshold: serum testosterone <264–300 ng/dL on at least 2 fasting morning samples (7–10 am) using a validated, externally quality-controlled assay
• In obese men, ≥5% weight loss typically produces a significant increase in serum total testosterone
• Weight loss in obese men is associated with improved physical function, libido, and erectile function

Study Quality

This is a narrative review published in JAMA, not a systematic review or meta-analysis, so it reflects the authors' synthesis of the literature rather than a preregistered, exhaustive search with pooled effect sizes. The three authors are academic endocrinologists with direct clinical expertise in hypogonadism; the University of Washington group has published extensively on testosterone assay methodology and diagnostic thresholds. The review covers pathophysiology, diagnosis, and management coherently, and the diagnostic criteria cited (264–300 ng/dL on two fasting morning samples with quality-controlled assay) align with current Endocrine Society guidelines, lending it some external validity.

The weight-loss claim — that ≥5% weight loss "typically" increases testosterone "significantly" — is stated without citing a specific trial or meta-analysis in the abstract. How large the increase is, whether it crosses the diagnostic threshold, and how durable the effect is at different degrees of weight loss remain unquantified here. The range "264–300 ng/dL" for the diagnostic cutoff reflects genuine disagreement across guidelines; the review does not adjudicate between them.

Red Flags

• Narrative (non-systematic) review: inclusion criteria for underlying studies are not stated, and selection bias is impossible to assess
• Funding and conflicts of interest not disclosed — notable for a JAMA review on a topic with substantial industry involvement (testosterone therapy is a large commercial market)
• The 2–8% obesity-hypogonadism prevalence range is wide enough to suggest the underlying studies vary considerably in population, assay, and diagnostic criteria
• No quantification of the testosterone increase associated with weight loss (effect size, duration, responder rate)
• The abstract conflates "statistically significant" increase with clinically meaningful increase for the weight-loss claim

Strengths

• Published in JAMA with institutional authorship from two established academic endocrinology programs
• Clear diagnostic framework: two fasting morning samples, validated assay, free testosterone calculation for obese/diabetic/low-SHBG patients
• Distinguishes primary from secondary hypogonadism mechanistically (LH/FSH pattern), which is clinically useful framing
• Correctly identifies Klinefelter syndrome as underdiagnosed — relevant given its 1-in-500 prevalence
• Explicitly lists reversible causes (opioids, corticosteroids, checkpoint inhibitors) that are often overlooked in clinical practice
• Restraint on testosterone prescribing: the review does not endorse testosterone for functional/obesity-related hypogonadism

Verdict

A competent, well-scoped review from credible academic endocrinologists that delivers a clear and important message: most low testosterone is secondary to obesity or medications, not primary gonadal failure, and the first intervention for the former is weight loss rather than testosterone therapy. Its limitations are the standard limitations of narrative reviews — no systematic search, no pooled data, no effect sizes on the weight-loss benefit — and the undisclosed COI is a gap for a topic this commercially loaded. Worth reading for the diagnostic framework and the prevalence hierarchy, but readers wanting quantified effect sizes for the weight-loss benefit will need to go to the primary literature.